메뉴 건너뛰기




Volumn 22, Issue 1, 2010, Pages 17-27

A comparison of the clinical effectiveness and cost-effectiveness of treatments for moderate to severe psoriasis

Author keywords

Cost effectiveness; Psoriasis; Psoriasis area and severity index

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; METHOXSALEN;

EID: 77949314680     PISSN: 10805826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (10)

References (59)
  • 1
    • 0029887202 scopus 로고    scopus 로고
    • Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment
    • Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485-496.
    • (1996) Dermatol Clin , vol.14 , pp. 485-496
    • Koo, J.1
  • 3
    • 1842555395 scopus 로고    scopus 로고
    • Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction
    • Stem RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136-139.
    • (2004) J Investig Dermatol Symp Proc , vol.9 , pp. 136-139
    • Stem, R.S.1    Nijsten, T.2    Feldman, S.R.3
  • 5
    • 14244258610 scopus 로고    scopus 로고
    • Psoriasis pathophysiology: Current concepts of pathogenesis
    • Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64(suppl 2):ii30-ii36.
    • (2005) Ann Rheum Dis , vol.64 , Issue.SUPPL. 2
    • Krueger, J.G.1    Bowcock, A.2
  • 6
    • 0032872277 scopus 로고    scopus 로고
    • Psoriasis causes as much disability as other major medical diseases
    • Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 pt 1):401-407.
    • (1999) J Am Acad Dermatol , vol.41 , Issue.3 PART 1 , pp. 401-407
    • Rapp, S.R.1    Feldman, S.R.2    Exum, M.L.3
  • 7
    • 77949316248 scopus 로고    scopus 로고
    • The Lewin Group Inc, Prepared for the Society for Investigative Dermatology and the American Academy of Dermatology Association, Accessed October 14, 2008
    • The Lewin Group Inc. The Burden of Skin Diseases 2004. Prepared for the Society for Investigative Dermatology and the American Academy of Dermatology Association. http://www.sidnet.org/pdfs/Burden%20of%20Skin%20Diseases%202004. pdf. Accessed October 14, 2008.
    • (2004) The Burden of Skin Diseases
  • 8
    • 0036621075 scopus 로고    scopus 로고
    • The direct cost of care for psoriasis and psoriatic arthritis in the United States
    • Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol. 2002;46:850-860.
    • (2002) J Am Acad Dermatol , vol.46 , pp. 850-860
    • Javitz, H.S.1    Ward, M.M.2    Farber, E.3
  • 9
    • 33646441017 scopus 로고    scopus 로고
    • The cost of psoriasis
    • 5suppl:10- 13
    • Crown WH. The cost of psoriasis. Manag Care. 2003;12(5suppl):10- 13.
    • (2003) Manag Care , pp. 12
    • Crown, W.H.1
  • 10
    • 77949322158 scopus 로고    scopus 로고
    • Research Pipeline. Treatments in Development for Psoriasis and/or Psoriatic Arthritis, Accessed October 14, 2008
    • National Psoriasis Foundation. National Psoriasis Foundation 2008 Research Pipeline. Treatments in Development for Psoriasis and/or Psoriatic Arthritis, http://www.psoriasis.org/files/pdfs/research/pipeline-03-08ltr.pdf. Accessed October 14, 2008.
    • (2008)
  • 12
    • 41849102049 scopus 로고    scopus 로고
    • A strategic plan for integrating cost-effectiveness analysis into the US healthcare system
    • Neumann PJ, Palmer JA, Daniels N, et al. A strategic plan for integrating cost-effectiveness analysis into the US healthcare system. Am J Manag Care. 2008;14:185-188.
    • (2008) Am J Manag Care , vol.14 , pp. 185-188
    • Neumann, P.J.1    Palmer, J.A.2    Daniels, N.3
  • 13
    • 85136365594 scopus 로고    scopus 로고
    • Justice AC, Cho MK, Winker MA, et al. Does masking author identity improve peer review quality? A randomized controlled trial. PEER Investigators [published correction appears in JAMA. 1998;80:968. JAMA. 1998;280:240-242.
    • Justice AC, Cho MK, Winker MA, et al. Does masking author identity improve peer review quality? A randomized controlled trial. PEER Investigators [published correction appears in JAMA. 1998;80:968). JAMA. 1998;280:240-242.
  • 14
    • 0038120138 scopus 로고    scopus 로고
    • Appraising systematic reviews and meta-analyses
    • Bigby M, Williams H. Appraising systematic reviews and meta-analyses. Arch Dermatol. 2003;139:795-798.
    • (2003) Arch Dermatol , vol.139 , pp. 795-798
    • Bigby, M.1    Williams, H.2
  • 15
    • 0041632271 scopus 로고    scopus 로고
    • Psoriasis treatment 2003 at the new millennium: Position paper on behalf of the authors
    • Menter MA, Krueger GC, Feldman SR, Weinstein GD. Psoriasis treatment 2003 at the new millennium: position paper on behalf of the authors. J Am Acad Dermatol. 2003;49(2 suppl):S39-S43.
    • (2003) J Am Acad Dermatol , vol.49 , Issue.2 SUPPL.
    • Menter, M.A.1    Krueger, G.C.2    Feldman, S.R.3    Weinstein, G.D.4
  • 16
    • 0141955042 scopus 로고    scopus 로고
    • Psoriasis disease severity measures: Comparing efficacy of treatments for severe psoriasis
    • Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat. 2003;14:158-165.
    • (2003) J Dermatolog Treat , vol.14 , pp. 158-165
    • Weisman, S.1    Pollack, C.R.2    Gottschalk, R.W.3
  • 17
    • 0018099294 scopus 로고
    • Severe psoriasis - oral therapy with a new retinoid
    • Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244.
    • (1978) Dermatologica , vol.157 , Issue.4 , pp. 238-244
    • Fredriksson, T.1    Pettersson, U.2
  • 18
    • 2542445474 scopus 로고    scopus 로고
    • A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis
    • Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50:859-866.
    • (2004) J Am Acad Dermatol , vol.50 , pp. 859-866
    • Carlin, C.S.1    Feldman, S.R.2    Krueger, J.G.3
  • 19
    • 14244250511 scopus 로고    scopus 로고
    • Psoriasis assessment tools in clinical trials
    • Feldman SR, Kreuger GC. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(suppl 2):ii65-ii68.
    • (2005) Ann Rheum Dis , vol.64 , Issue.SUPPL. 2
    • Feldman, S.R.1    Kreuger, G.C.2
  • 20
    • 23944523103 scopus 로고    scopus 로고
    • A cost comparison of treatments for moderate to severe psoriasis
    • HankinCS, Feldman SR, Szczotka A, etal. A cost comparison of treatments for moderate to severe psoriasis. Drug Benefit Trends. 2005;17:200-214.
    • (2005) Drug Benefit Trends , vol.17 , pp. 200-214
    • Hankin, C.S.1    Feldman, S.R.2    Szczotka, A.3
  • 21
    • 37349061697 scopus 로고    scopus 로고
    • Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period
    • Nelson AA, Pearce DJ, Fleischer AB Jr, et al. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008;58:125-135.
    • (2008) J Am Acad Dermatol , vol.58 , pp. 125-135
    • Nelson, A.A.1    Pearce, D.J.2    Fleischer Jr, A.B.3
  • 22
    • 33144473657 scopus 로고    scopus 로고
    • Cost-effectiveness of moderate-to-severe psoriasis treatment
    • Miller DW, Feldman SR. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother. 2006;7:157-167.
    • (2006) Expert Opin Pharmacother , vol.7 , pp. 157-167
    • Miller, D.W.1    Feldman, S.R.2
  • 23
    • 77949329781 scopus 로고    scopus 로고
    • Amevive package insert, Cambridge, MA: Biogen, Inc; 2003
    • Amevive (package insert]. Cambridge, MA: Biogen, Inc; 2003.
  • 24
    • 77949319469 scopus 로고    scopus 로고
    • Raptiva [package insert, South San Francisco, CA: Genentech, Inc; 2005
    • Raptiva [package insert]. South San Francisco, CA: Genentech, Inc; 2005.
  • 25
    • 77949329231 scopus 로고    scopus 로고
    • Enbrel [package insert, Thousand Oaks, CA: Immunex Corporation; 2009
    • Enbrel [package insert]. Thousand Oaks, CA: Immunex Corporation; 2009.
  • 26
    • 77949333200 scopus 로고    scopus 로고
    • Humira [package insert, North Chicago, IL: Abbott Laboratories; 2008
    • Humira [package insert]. North Chicago, IL: Abbott Laboratories; 2008.
  • 27
    • 69749085182 scopus 로고    scopus 로고
    • Long-term efficacy of biologics in the treatment of psoriasis: What do we really know?
    • Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther. 2009;22:431-440.
    • (2009) Dermatol Ther , vol.22 , pp. 431-440
    • Alwawi, E.A.1    Krulig, E.2    Gordon, K.B.3
  • 28
    • 60649105419 scopus 로고    scopus 로고
    • Long-term efficacy of biologics in dermatology
    • Castelo-Soccio L, Van Voorhees AS. Long-term efficacy of biologics in dermatology. Dermatol Ther. 2009;22:22-33.
    • (2009) Dermatol Ther , vol.22 , pp. 22-33
    • Castelo-Soccio, L.1    Van Voorhees, A.S.2
  • 29
    • 77949319828 scopus 로고    scopus 로고
    • Effect of disease and low-dose maintenance acitretin for plaque-type psoriasis
    • Poster presented at: March 3-7, San Francisco
    • Cather J, Krueger G, Rowell R, et al. Effect of disease and low-dose maintenance acitretin for plaque-type psoriasis. Poster presented at: the 64th Annual Meeting of the American Academy of Dermatology; March 3-7,2006; San Francisco.
    • (2006) the 64th Annual Meeting of the American Academy of Dermatology
    • Cather, J.1    Krueger, G.2    Rowell, R.3
  • 31
    • 78650106911 scopus 로고    scopus 로고
    • McDowell MA, Fryar CD, Ogden CL, Flegal KM. Anthropometric reference data for children and adults: United States, 2003-2006. National health statistics reports; no 10. Hyattsville, MD: National Center for Health Statistics; 2008.
    • McDowell MA, Fryar CD, Ogden CL, Flegal KM. Anthropometric reference data for children and adults: United States, 2003-2006. National health statistics reports; no 10. Hyattsville, MD: National Center for Health Statistics; 2008.
  • 32
    • 0036884653 scopus 로고    scopus 로고
    • Management of guttate and generalized psoriasis vulgaris: Prospective randomized study
    • Caca-Biljanovska NG, V'Ickova-Laskoska MT. Management of guttate and generalized psoriasis vulgaris: prospective randomized study. Croat Med J. 2002;43:707-712.
    • (2002) Croat Med J , vol.43 , pp. 707-712
    • Caca-Biljanovska, N.G.1    V'Ickova-Laskoska, M.T.2
  • 33
    • 0025877405 scopus 로고
    • Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone
    • Lowe NJ, Prystowsky JH, Bourget T, et al. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol. 1991;24:591-594.
    • (1991) J Am Acad Dermatol , vol.24 , pp. 591-594
    • Lowe, N.J.1    Prystowsky, J.H.2    Bourget, T.3
  • 34
    • 0027495835 scopus 로고
    • Relapse rate of severe generalized psoriasis after treatment with acitretin or etretinate. Results of the first randomized double-blind multicenter half-year follow-up study
    • Gollnick H, Zaun H, Ruzicka T, et al. Relapse rate of severe generalized psoriasis after treatment with acitretin or etretinate. Results of the first randomized double-blind multicenter half-year follow-up study. Eur J Dermatol. 1993;3:442-446.
    • (1993) Eur J Dermatol , vol.3 , pp. 442-446
    • Gollnick, H.1    Zaun, H.2    Ruzicka, T.3
  • 35
    • 0034786155 scopus 로고    scopus 로고
    • Sirolimus European Psoriasis Study Group. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: A randomized controlled trial
    • Reitamo S, Spuls P, Sassolas B, et al; Sirolimus European Psoriasis Study Group. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol. 2001;145:438-445.
    • (2001) Br J Dermatol , vol.145 , pp. 438-445
    • Reitamo, S.1    Spuls, P.2    Sassolas, B.3
  • 36
    • 0026013163 scopus 로고
    • Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial
    • Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med. 1991;324:277-284.
    • (1991) N Engl J Med , vol.324 , pp. 277-284
    • Ellis, C.N.1    Fradin, M.S.2    Messana, J.M.3
  • 37
    • 0036039938 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis
    • Chládek J, Grim J, Martinková J, et al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol. 2002;54:147-156.
    • (2002) Br J Clin Pharmacol , vol.54 , pp. 147-156
    • Chládek, J.1    Grim, J.2    Martinková, J.3
  • 38
    • 39049143819 scopus 로고    scopus 로고
    • CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
    • Saurat JH, Stingl G, Dubertret L, et al; CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558-566.
    • (2008) Br J Dermatol , vol.158 , pp. 558-566
    • Saurat, J.H.1    Stingl, G.2    Dubertret, L.3
  • 39
    • 33748936662 scopus 로고    scopus 로고
    • Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
    • Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55:598-606.
    • (2006) J Am Acad Dermatol , vol.55 , pp. 598-606
    • Gordon, K.B.1    Langley, R.G.2    Leonardi, C.3
  • 40
    • 37349003068 scopus 로고    scopus 로고
    • Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
    • Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-115.
    • (2008) J Am Acad Dermatol , vol.58 , pp. 106-115
    • Menter, A.1    Tyring, S.K.2    Gordon, K.3
  • 41
    • 0038385972 scopus 로고    scopus 로고
    • An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis
    • Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003;139:719-727.
    • (2003) Arch Dermatol , vol.139 , pp. 719-727
    • Lebwohl, M.1    Christophers, E.2    Langley, R.3
  • 42
    • 0345107256 scopus 로고    scopus 로고
    • Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis
    • Lebwohl M, Tyring SK, Hamilton TK, et al; Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-2013.
    • (2003) N Engl J Med , vol.349 , pp. 2004-2013
    • Lebwohl, M.1    Tyring, S.K.2    Hamilton, T.K.3
  • 43
    • 33745038011 scopus 로고    scopus 로고
    • CLEAR Multinational Study Group. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from a phase III international randomized, placebo-controlled trial
    • Dubertret L, Sterry W, Bos JD, et al; CLEAR Multinational Study Group. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol. 2006;155:170-181.
    • (2006) Br J Dermatol , vol.155 , pp. 170-181
    • Dubertret, L.1    Sterry, W.2    Bos, J.D.3
  • 44
    • 17144388751 scopus 로고    scopus 로고
    • Efalizumab Study Group. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial
    • Leonardi CL, Papp KA, Gordon KB, et al; Efalizumab Study Group. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005;52(3 pt 1):425-433.
    • (2005) J Am Acad Dermatol , vol.52 , Issue.3 PART 1 , pp. 425-433
    • Leonardi, C.L.1    Papp, K.A.2    Gordon, K.B.3
  • 45
    • 12444336904 scopus 로고    scopus 로고
    • Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis
    • Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141:31-38.
    • (2005) Arch Dermatol , vol.141 , pp. 31-38
    • Menter, A.1    Gordon, K.2    Carey, W.3
  • 46
    • 0344926414 scopus 로고    scopus 로고
    • Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis
    • Leonardi CL, Powers JL, Matheson RT, et al; Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-2022.
    • (2003) N Engl J Med , vol.349 , pp. 2014-2022
    • Leonardi, C.L.1    Powers, J.L.2    Matheson, R.T.3
  • 47
    • 21644481166 scopus 로고    scopus 로고
    • Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction
    • Papp KA, Tyring S, Lahfa M, et al; Etanercept Psoriasis Study Group. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312.
    • (2005) Br J Dermatol , vol.152 , pp. 1304-1312
    • Papp, K.A.1    Tyring, S.2    Lahfa, M.3
  • 48
    • 0035832515 scopus 로고    scopus 로고
    • Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised triaL
    • Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised triaL Lancet. 2001;357:1842-1847.
    • (2001) Lancet , vol.357 , pp. 1842-1847
    • Chaudhari, U.1    Romano, P.2    Mulcahy, L.D.3
  • 49
    • 0033967598 scopus 로고    scopus 로고
    • Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: A safe, effective and UVB-sparing antipsoriatic combination treatment. The Canadian Calcipotriol and UVB Study Group
    • Ramsay CA, Schwartz BE, Lowson D, et al. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatic combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology. 2000;200:17-24.
    • (2000) Dermatology , vol.200 , pp. 17-24
    • Ramsay, C.A.1    Schwartz, B.E.2    Lowson, D.3
  • 50
    • 0034745160 scopus 로고    scopus 로고
    • Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: Results of a comparative study
    • Ring J, Kowalzick L, Christophers E, et al. Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. Br J Dermatol. 2001;144:495-499.
    • (2001) Br J Dermatol , vol.144 , pp. 495-499
    • Ring, J.1    Kowalzick, L.2    Christophers, E.3
  • 51
    • 0041633617 scopus 로고    scopus 로고
    • Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: A prospective randomized placebo-controlled clinical trial
    • Woo WK, McKenna KE. Combination TL01 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo-controlled clinical trial. Br J Dermatol. 2003;149:146-150.
    • (2003) Br J Dermatol , vol.149 , pp. 146-150
    • Woo, W.K.1    McKenna, K.E.2
  • 52
    • 1842663103 scopus 로고    scopus 로고
    • A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris
    • Torras H, Aliaga A, Lopez-Estebaranz JL, et al. A combination therapy of calcipotriol cream and PUVA reduces the UVA dose and improves the response of psoriasis vulgaris. J Dermatolog Treat. 2004;15:98-103.
    • (2004) J Dermatolog Treat , vol.15 , pp. 98-103
    • Torras, H.1    Aliaga, A.2    Lopez-Estebaranz, J.L.3
  • 53
    • 0024312928 scopus 로고
    • A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis
    • Lauharanta J, Geiger JM. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol. 1989;121:107-112.
    • (1989) Br J Dermatol , vol.121 , pp. 107-112
    • Lauharanta, J.1    Geiger, J.M.2
  • 54
    • 77949322374 scopus 로고    scopus 로고
    • Soriatane [package insert, Coral Gables, FL: Stiefel Laboratories, Inc; 2007
    • Soriatane [package insert]. Coral Gables, FL: Stiefel Laboratories, Inc; 2007.
  • 55
    • 77949328630 scopus 로고    scopus 로고
    • Neoral [package insert, East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005
    • Neoral [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005.
  • 56
    • 77949328753 scopus 로고    scopus 로고
    • Trexall [package insert, Pomona, NY: Duramed Pharmaceuticals, Inc; 2005
    • Trexall [package insert]. Pomona, NY: Duramed Pharmaceuticals, Inc; 2005.
  • 57
    • 77949328156 scopus 로고    scopus 로고
    • Remicade [package insert, Malvern, PA: Centocor, Inc; 2007
    • Remicade [package insert]. Malvern, PA: Centocor, Inc; 2007.
  • 58
    • 33645442412 scopus 로고    scopus 로고
    • The art and practice of UVB phototherapy for the treatment of psoriasis
    • Weinstein GD, Gottleib AB, eds, Second Edition, Revised and Expanded. 2nd ed. New York: Marcel Dekker, Inc;
    • Koo J, Bandow G, Feldman SR. The art and practice of UVB phototherapy for the treatment of psoriasis. In: Weinstein GD, Gottleib AB, eds. Therapy of Moderate-to-Severe Psoriasis: Second Edition, Revised and Expanded. 2nd ed. New York: Marcel Dekker, Inc; 2003:53-90.
    • (2003) Therapy of Moderate-to-Severe Psoriasis , pp. 53-90
    • Koo, J.1    Bandow, G.2    Feldman, S.R.3
  • 59
    • 10844235760 scopus 로고    scopus 로고
    • Systemic and topical PUVA therapy
    • Weinstein GD, Gottlieb AB, eds, Second Edition, Revised and Expanded. 2nd ed. New York: Marcel Dekker;
    • Morison WL. Systemic and topical PUVA therapy. In: Weinstein GD, Gottlieb AB, eds. Therapy of Moderate-to-Severe Psoriasis: Second Edition, Revised and Expanded. 2nd ed. New York: Marcel Dekker; 2003:91-114.
    • (2003) Therapy of Moderate-to-Severe Psoriasis , pp. 91-114
    • Morison, W.L.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.